FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800754367> ?p ?o ?g. }

• W2800754367 endingPage "10040" @default.
• W2800754367 startingPage "10026" @default.
• W2800754367 abstract "Asthma is a chronic inflammatory disease of the lungs and airways and one of the most burdensome of all chronic maladies. Previous studies have established that expression of experimental and human asthma requires the IL-4/IL-13/IL-4 receptor α (IL-4Rα) signaling pathway, which activates the transcription factor STAT6. However, no small molecules targeting this important pathway are currently in clinical development. To this end, using a preclinical asthma model, we sought to develop and test a small-molecule inhibitor of the Src homology 2 domains in mouse and human STAT6. We previously developed multiple peptidomimetic compounds on the basis of blocking the docking site of STAT6 to IL-4Rα and phosphorylation of Tyr641 in STAT6. Here, we expanded the scope of our initial in vitro structure–activity relationship studies to include central and C-terminal analogs of these peptides to develop a lead compound, PM-43I. Conducting initial dose range, toxicity, and pharmacokinetic experiments with PM-43I, we found that it potently inhibits both STAT5- and STAT6-dependent allergic airway disease in mice. Moreover, PM-43I reversed preexisting allergic airway disease in mice with a minimum ED50 of 0.25 μg/kg. Of note, PM-43I was efficiently cleared through the kidneys with no long-term toxicity. We conclude that PM-43I represents the first of a class of small molecules that may be suitable for further clinical development against asthma. Asthma is a chronic inflammatory disease of the lungs and airways and one of the most burdensome of all chronic maladies. Previous studies have established that expression of experimental and human asthma requires the IL-4/IL-13/IL-4 receptor α (IL-4Rα) signaling pathway, which activates the transcription factor STAT6. However, no small molecules targeting this important pathway are currently in clinical development. To this end, using a preclinical asthma model, we sought to develop and test a small-molecule inhibitor of the Src homology 2 domains in mouse and human STAT6. We previously developed multiple peptidomimetic compounds on the basis of blocking the docking site of STAT6 to IL-4Rα and phosphorylation of Tyr641 in STAT6. Here, we expanded the scope of our initial in vitro structure–activity relationship studies to include central and C-terminal analogs of these peptides to develop a lead compound, PM-43I. Conducting initial dose range, toxicity, and pharmacokinetic experiments with PM-43I, we found that it potently inhibits both STAT5- and STAT6-dependent allergic airway disease in mice. Moreover, PM-43I reversed preexisting allergic airway disease in mice with a minimum ED50 of 0.25 μg/kg. Of note, PM-43I was efficiently cleared through the kidneys with no long-term toxicity. We conclude that PM-43I represents the first of a class of small molecules that may be suitable for further clinical development against asthma." @default.
• W2800754367 created "2018-05-17" @default.
• W2800754367 creator A5000188643 @default.
• W2800754367 creator A5002323793 @default.
• W2800754367 creator A5013602233 @default.
• W2800754367 creator A5032651261 @default.
• W2800754367 creator A5039771630 @default.
• W2800754367 creator A5060702881 @default.
• W2800754367 creator A5062277760 @default.
• W2800754367 creator A5062505813 @default.
• W2800754367 creator A5066396232 @default.
• W2800754367 creator A5067889643 @default.
• W2800754367 creator A5069020976 @default.
• W2800754367 creator A5071134906 @default.
• W2800754367 creator A5072125087 @default.
• W2800754367 creator A5075221044 @default.
• W2800754367 creator A5077013841 @default.
• W2800754367 creator A5084607533 @default.
• W2800754367 date "2018-06-01" @default.
• W2800754367 modified "2023-10-18" @default.
• W2800754367 title "Small molecule targeting of the STAT5/6 Src homology 2 (SH2) domains to inhibit allergic airway disease" @default.
• W2800754367 cites W1488478985 @default.
• W2800754367 cites W1491964046 @default.
• W2800754367 cites W1552266425 @default.
• W2800754367 cites W1656645373 @default.
• W2800754367 cites W1957571574 @default.
• W2800754367 cites W1967818318 @default.
• W2800754367 cites W1978385213 @default.
• W2800754367 cites W1985348626 @default.
• W2800754367 cites W1988186204 @default.
• W2800754367 cites W1992312343 @default.
• W2800754367 cites W1997352945 @default.
• W2800754367 cites W1999996757 @default.
• W2800754367 cites W2002375125 @default.
• W2800754367 cites W2002375890 @default.
• W2800754367 cites W2002594435 @default.
• W2800754367 cites W2003334714 @default.
• W2800754367 cites W2008293419 @default.
• W2800754367 cites W2008479676 @default.
• W2800754367 cites W2020875289 @default.
• W2800754367 cites W2020895935 @default.
• W2800754367 cites W2022258692 @default.
• W2800754367 cites W2033829532 @default.
• W2800754367 cites W2037316198 @default.
• W2800754367 cites W2039427369 @default.
• W2800754367 cites W2052172628 @default.
• W2800754367 cites W2052519854 @default.
• W2800754367 cites W2058856567 @default.
• W2800754367 cites W2061005208 @default.
• W2800754367 cites W2061435251 @default.
• W2800754367 cites W2065801967 @default.
• W2800754367 cites W2068406274 @default.
• W2800754367 cites W2071523811 @default.
• W2800754367 cites W2079847100 @default.
• W2800754367 cites W2096912349 @default.
• W2800754367 cites W2101687009 @default.
• W2800754367 cites W2113552278 @default.
• W2800754367 cites W2122384715 @default.
• W2800754367 cites W2124566107 @default.
• W2800754367 cites W2124976285 @default.
• W2800754367 cites W2125805192 @default.
• W2800754367 cites W2127482775 @default.
• W2800754367 cites W2136810169 @default.
• W2800754367 cites W2143374279 @default.
• W2800754367 cites W2151444009 @default.
• W2800754367 cites W2157888813 @default.
• W2800754367 cites W2160989271 @default.
• W2800754367 cites W2162022916 @default.
• W2800754367 cites W2167829087 @default.
• W2800754367 cites W2177742114 @default.
• W2800754367 cites W2271298233 @default.
• W2800754367 cites W2312640764 @default.
• W2800754367 cites W2316669982 @default.
• W2800754367 cites W2323461670 @default.
• W2800754367 cites W2341539969 @default.
• W2800754367 cites W2405897684 @default.
• W2800754367 cites W2417616679 @default.
• W2800754367 cites W2419292540 @default.
• W2800754367 cites W2509074682 @default.
• W2800754367 cites W2516368372 @default.
• W2800754367 cites W2557403528 @default.
• W2800754367 cites W2559023589 @default.
• W2800754367 doi "https://doi.org/10.1074/jbc.ra117.000567" @default.
• W2800754367 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6028980" @default.
• W2800754367 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29739850" @default.
• W2800754367 hasPublicationYear "2018" @default.
• W2800754367 type Work @default.
• W2800754367 sameAs 2800754367 @default.
• W2800754367 citedByCount "15" @default.
• W2800754367 countsByYear W28007543672019 @default.
• W2800754367 countsByYear W28007543672020 @default.
• W2800754367 countsByYear W28007543672021 @default.
• W2800754367 countsByYear W28007543672022 @default.
• W2800754367 countsByYear W28007543672023 @default.
• W2800754367 crossrefType "journal-article" @default.
• W2800754367 hasAuthorship W2800754367A5000188643 @default.
• W2800754367 hasAuthorship W2800754367A5002323793 @default.
• W2800754367 hasAuthorship W2800754367A5013602233 @default.

• next